KIT and neoplasm: Immunohistochemical analysis of several RTKs (VEGFR1/2/3, PDGFRα/β and c-Kit) in a set of 81 MGMs from 74 patients showed that twenty-nine grade I (45%), ten grade II (77%), and four grade III (100%) tumors were VEGFR2-positive, and VEGFR2 expression was significantly correlated with tumor grade [85].